Innovative Approaches in ALS Treatment Showcased at AD/PD 2024 International Conference
The AD/PD 2024 International Conference highlighted innovative approaches for revolutionizing ALS treatment, emphasizing the urgent need for disease-modifying therapies. Discussions also focused on the use of neurochemical biomarkers in ALS drug development, signaling a potential shift towards more precise and targeted treatment approaches.
Biogen Terminates Phase 4 Trial for Aducanumab, Transfers Ownership Rights
Biogen, the pharmaceutical company behind the development of aducanumab, has announced the termination of the Phase 4 trial mandated by the FDA for the drug. Aducanumab, a monoclonal antibody targeting beta-amyloid, had received accelerated approval in 2021. However, the company…